The overall study design is presented in Figure 1. Figure 1.Overall Study Design Protocol B7791001 Statistical Analysis Plan PFIZER CONFIDENTIAL Page 62.2. Study Objectives Part A Primary Objective •To assess safety and tolerability of increasing dose levels of the prostate cancer vaccine-based immunotherapy regimen (PrCa VBIR) components alone and in combination with increasing doses of PF-06801591. •To characterize the dose limiting toxicities (DLTs), if any are observed, and overall safety profile of escalated doses of the PrCa VBIR components alone and in combination with increasing doses of PF-06801591. •To determine the Part B Expansion Dose for the PrCa VBIR components, and in combination with PF-06801591. Part A Secondary Objectives •To evaluate the immune response elicited by the PrCa VBIR to the selected prostate cancer tumor-antigens. •To evaluate the overall safety profile in prostate cancer participants. •To evaluate the PK of tremelimumab after subcutaneous(SC) administration. •To evaluate the PK of PF-06801591 after SC administration •To evaluate the anti-drug antibody (ADA) response of tremelimumab after SC administration with the other PrCa VBIR components. •To evaluate the ADA response of PF-06801591 after SC administration with the other PrCa VBIR components. Part A Exploratory Objectives •To document any preliminary evidence of anti-tumor activity. Part B Primary Objective •To evaluate the overall safety profile of the PrCa VBIR + PF-06801591 in prostate cancer participants. Part B Secondary ObjectivesCCI Protocol B7791001 Statistical Analysis Plan PFIZER CONFIDENTIAL Page 7•For Cohort 3B: To evaluate the anti-tumor response induced by treatment in participants with mCRPC utilizing solid tumor response criteria. •For Cohort 3B: To evaluate the anti-tumor response induced by treatment utilizing immune related response criteria. •For Cohort 3B: to evaluate bone metastatic disease outcome in participants with mCRPC. •For Cohorts 3B: To estimate the duration of radiographic Progression-Free Survival (rPFS) in participants with mCRPC. •To evaluate response rate based on 50% reduction of prostate specific antigen (PSA). •To evaluate PSA kinetics. •To evaluate trough concentrations of tremelimumab after SC administration at selected doses. •To evaluate trough concentrations of PF-06801591 after SC administration at selected doses. •To evaluate the anti-drug antibody (ADA) response of tremelimumab after SC administration with the other PrCa VBIR components. •To evaluate the ADA response of PF-06801591 after SC administration with the other PrCa VBIR components. 3.